ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sarepta buys into Lysogene gene therapy

by Lisa M. Jarvis
October 19, 2018 | APPEARED IN VOLUME 96, ISSUE 42

 

In another deal to bolster its gene-therapy pipeline, Sarepta Therapeutics will pay Lysogene $26 million for access to LYS-SAF302, a gene therapy for a rare and fatal lysosomal storage disorder called MPS IIIA. The deal gives Sarepta full rights to the therapy in the U.S. and in markets outside Europe. It will also take on global manufacturing of the treatment. Sarepta created a gene-therapy unit earlier this year and has since assembled a portfolio of potential treatments through licensing deals and acquisitions.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment